Featured Research

from universities, journals, and other organizations

Volunteers Sought For Study On Whether Antibiotics Can Reduce Heart Disease Risk

Date:
August 10, 1999
Source:
Wake Forest University School Of Medicine
Summary:
Doctors at Wake Forest University Baptist Medical Center and 25 other centers will test whether antibiotics can reduce the risk of heart attacks and strokes. "The study is to determine whether heart disease is an infectious disease that can be treated with an antibiotic," said John R. Crouse III, M.D., professor of internal medicine (endocrinology) and public health sciences.

WINSTON-SALEM, N.C. -- Doctors at Wake Forest University Baptist Medical Center and 25 other centers will test whether antibiotics can reduce the risk of heart attacks and strokes.

Related Articles


"The study is to determine whether heart disease is an infectious disease that can be treated with an antibiotic," said John R. Crouse III, M.D., professor of internal medicine (endocrinology) and public health sciences, who will head the Wake Forest component of the national clinical trial. "We think it is a really exciting study."

Medical researchers have found that a common type of bacteria, called Chlamydia pneumoniae, may be associated with atherosclerosis -- hardening of the arteries. Nearly everybody gets a respiratory infection caused by Chlamydia pneumoniae at some time in their lives, and severe infections can lead to bronchitis and pneumonia.

In the late 1980s, Chlamydia pneumoniae was discovered in samples of diseased coronary artery tissue. Two small trials showed positive results when patients with heart disease were treated with an antibiotic.

The national clinical trial was the outgrowth of those pilot studies. In the trial, to be called the Azithromycin and Coronary Event Study (ACES), doctors will test whether the antibiotic azithromycin (Zithromax) will reduce the risk of heart attacks and strokes.

About 4,000 volunteers will be recruited nationally. Participants will be assigned at random to either a control group that will receive a placebo or the treatment group that will receive azithromycin. For one year, each participant will take one pill each week. Otherwise, participants will not be asked to change their current treatment for heart disease.

They will be followed for three more years to monitor for any coronary events, including hospitalization for heart attack, chest pain, coronary artery bypass grafts, balloon angioplasty (or other similar treatments), or if they die because of complications of coronary artery disease.

"We already have randomized our first 25 patients," Crouse said. "We hope to recruit 150-180 patients for the study."

J. Thomas Grayston, a pioneer in chlamydia research at the University of Washington in Seattle, is the national study director.

"The idea of giving antibiotics to treat a chronic disease like coronary artery disease is not as far-fetched an idea as it once was," said Grayston. "This clinical trial should help prove whether the Chlamydia pneumoniae bacteria plays a direct role in the development or advancement of atherosclerosis.

For more than 40 years, researchers at Wake Forest have pioneered in the study of atherosclerosis, finding that first the pigeon and then the monkey were ideal animal models that would develop the disease when fed a typical American diet. Wake Forest research helped pin down the role of various dietary fats and cholesterol in the development of atherosclerosis.

Despite the research, scientists have only been able to explain about half the heart disease with such risk factors as high blood pressure, smoking, high cholesterol, lack of exercise, obesity and diabetes. For the past decade, they have been searching for other answers.

Coronary artery atherosclerosis that is accelerated by infections such as Chlamydia pneumoniae could be part of that answer.

The 26 centers also include the University of North Carolina at Chapel Hill. The study is being paid for by an $11 million grant from the National Heart, Lung and Blood Institute. Pfizer Corp., the sole producer of azithromycin (Zithromax), is providing the study drug.

To be eligible for the study, a person must already have documented heart disease -- from a prior heart attack, from at least a 50 percent blockage of one or more coronary arteries that shows up in heart catheterization, from a prior coronary artery bypass graft, or from a procedure such as balloon angioplasty to clear a clogged artery. For more information, call Greg Terry (336)716-2679 or Telle King (336)716-2848.

# # #

Media Contact: Robert Conn ([email protected]) Jim Steele ([email protected]) or Mark Wright ([email protected]) at (336) 716-4587


Story Source:

The above story is based on materials provided by Wake Forest University School Of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Wake Forest University School Of Medicine. "Volunteers Sought For Study On Whether Antibiotics Can Reduce Heart Disease Risk." ScienceDaily. ScienceDaily, 10 August 1999. <www.sciencedaily.com/releases/1999/08/990810070643.htm>.
Wake Forest University School Of Medicine. (1999, August 10). Volunteers Sought For Study On Whether Antibiotics Can Reduce Heart Disease Risk. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/1999/08/990810070643.htm
Wake Forest University School Of Medicine. "Volunteers Sought For Study On Whether Antibiotics Can Reduce Heart Disease Risk." ScienceDaily. www.sciencedaily.com/releases/1999/08/990810070643.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins